H.C. Wainwright analyst Andrew Fein reiterated a Hold rating on Fulcrum Therapeutics (FULC – Research Report) today and set a price target of $4.00.
Andrew Fein has given his Hold rating due to a combination of factors surrounding Fulcrum Therapeutics’ ongoing PIONEER trial for pociredir in sickle cell disease. The trial’s upcoming data readouts in 2025 are critical, particularly regarding the efficacy of HbF induction, safety, and regulatory implications. The potential for pociredir to replace OXBRYTA, which was withdrawn from the market, adds a layer of complexity to the evaluation. Fein notes that while early data from healthy volunteers and patient cohorts have shown no significant safety concerns, the drug must continue to demonstrate an acceptable safety profile to advance further.
Moreover, the trial’s exclusion of patients on hydroxyurea due to regulatory restrictions presents a challenge, though Fulcrum plans to engage with the FDA to explore co-administration in future studies. The outcome of these engagements could significantly impact pociredir’s market potential. Fein’s Hold rating reflects a cautious optimism, as the drug’s future positioning as a first-line therapy depends on the magnitude of HbF induction and its safety profile in upcoming trial results.
According to TipRanks, Fein is a 3-star analyst with an average return of 2.4% and a 40.15% success rate. Fein covers the Healthcare sector, focusing on stocks such as Neurocrine, Palvella Therapeutics, and Vertex Pharmaceuticals.
Questions or Comments about the article? Write to editor@tipranks.com